{"id":474537,"date":"2021-04-10T08:38:32","date_gmt":"2021-04-10T12:38:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=474537"},"modified":"2021-04-10T08:38:32","modified_gmt":"2021-04-10T12:38:32","slug":"ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/","title":{"rendered":"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021"},"content":{"rendered":"

<\/p>\n

Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021<\/b><\/p>\n

OSLO, Norway–(BUSINESS WIRE<\/a>)–Ultimovacs ASA (“Ultimovacs”, ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Company\u2019s proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021.<\/b><\/p>\n

\nThe poster, titled, \u201cNivolumab and ipilimumab +\/- UV1 vaccine as 1st line treatment in patients with malignant melanoma (INITIUM-trial)\u201d, details the INITIUM study, a randomized, open label study investigating the efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as first line treatment in histologically confirmed unresectable metastatic melanoma patients. The INITIUM study is enrolling 154 patients, randomly assigned to the experimental arm or the control arm. Patients in the experimental arm will receive 8 UV1 vaccinations over 4 cycles of nivolumab and ipilimumab, whereas patients in the control arm will receive 4 cycles of nivolumab and ipilimumab without UV1 vaccination. In both arms, patients will start maintenance therapy with nivolumab after the last dose of induction therapy and will be followed until the end of the study. The primary outcome of the study is the Progression Free Survival (PFS) of patients in the experimental arm compared to patients in the control arm. Secondary outcomes include the comparison of Overall Survival (OS) and Objective Response Rate (ORR) between the groups.\n<\/p>\n

\nDetails of the presentation are as follows:\n<\/p>\n\n\n\n\n\n
\n

Title:<\/b><\/p>\n<\/td>\n

\n\n\n\n\n

\nNivolumab and ipilimumab +\/- UV1 vaccine as 1st line treatment in patients with malignant melanoma (INITIUM-trial)\n<\/p>\n<\/td>\n<\/tr>\n

\n

Session Type:<\/b><\/p>\n<\/td>\n

\n\n\n\n\n

\nE-poster Session\n<\/p>\n<\/td>\n<\/tr>\n

\n

Session Title:<\/b><\/p>\n<\/td>\n

\n\n\n\n\n

\nPhase II Clinical Trials in Progress\n<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract Number:<\/b><\/p>\n<\/td>\n

\n\n\n\n\n

\nCT23\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nThe poster is available on Ultimovacs\u2019 corporate website at www.ultimovacs.com<\/a>.\n<\/p>\n

About Ultimovacs<\/b><\/p>\n

\nUltimovacs seeks to become a leader in developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs\u2019 lead universal cancer vaccine candidate UV1 leverages the high prevalence of the human telomerase (hTERT) to be effective across the dynamic stages of the tumor\u2019s growth and its microenvironment. By directing the immune system to hTERT antigens that are present in over 80% of all cancers, UV1 drives CD4 helper T cells to the tumor with the goal of activating an immune system cascade to increase anti-tumor responses. Ultimovacs\u2019 strategy is to clinically demonstrate UV1\u2019s impact in many cancer types and in combination with other immunotherapies. The Company will expand its pipeline using its novel TET-platform, which is an innovative vaccine technology that can generate multiple vaccine candidates designed to achieve increased T cell responses to a broad range of target antigens.\n<\/p>\n

\nFor further information, please see www.ultimovacs.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210410005034\/en\/<\/a><\/span><\/p>\n

Carlos de Sousa, CEO
\n<\/b>
Email: carlos.desousa@ultimovacs.com
\n<\/a>
Phone: +47 908 92507\n<\/p>\n

Hans Vassg\u00e5rd Eid, CFO
\n<\/b>
Email: hans.eid@ultimovacs.com
\n<\/a>
Phone: +47 482 48632\n<\/p>\n

KEYWORDS:<\/b> Norway Europe United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 OSLO, Norway–(BUSINESS WIRE)–Ultimovacs ASA (“Ultimovacs”, ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Company\u2019s proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021. The poster, titled, \u201cNivolumab and ipilimumab +\/- UV1 vaccine as 1st line treatment in patients with malignant melanoma (INITIUM-trial)\u201d, details the INITIUM study, a randomized, open label study investigating the efficacy and safety of UV1 vaccination in combination with … <\/p>\n

Continue reading “Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-474537","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nUltimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 OSLO, Norway–(BUSINESS WIRE)–Ultimovacs ASA (“Ultimovacs”, ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Company\u2019s proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021. The poster, titled, \u201cNivolumab and ipilimumab +\/- UV1 vaccine as 1st line treatment in patients with malignant melanoma (INITIUM-trial)\u201d, details the INITIUM study, a randomized, open label study investigating the efficacy and safety of UV1 vaccination in combination with … Continue reading "Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-10T12:38:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210410005034r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021\",\"datePublished\":\"2021-04-10T12:38:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/\"},\"wordCount\":517,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210410005034r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/\",\"name\":\"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210410005034r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-04-10T12:38:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210410005034r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210410005034r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/","og_locale":"en_US","og_type":"article","og_title":"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 - Market Newsdesk","og_description":"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 OSLO, Norway–(BUSINESS WIRE)–Ultimovacs ASA (“Ultimovacs”, ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Company\u2019s proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021. The poster, titled, \u201cNivolumab and ipilimumab +\/- UV1 vaccine as 1st line treatment in patients with malignant melanoma (INITIUM-trial)\u201d, details the INITIUM study, a randomized, open label study investigating the efficacy and safety of UV1 vaccination in combination with … Continue reading \"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-10T12:38:32+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210410005034r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021","datePublished":"2021-04-10T12:38:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/"},"wordCount":517,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210410005034r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/","name":"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210410005034r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-04-10T12:38:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210410005034r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210410005034r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultimovacs-presents-the-initium-study-design-as-a-trial-in-progress-poster-at-aacr-annual-meeting-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=474537"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474537\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=474537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=474537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=474537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}